Adverse event reporting signals for SGLT-2 inhibitor–metformin combination therapy: a disproportionality analysis of the FAERS database
Objective This study aimed to evaluate the real-world safety profile of combination therapy with a sodium-glucose cotransporter-2 inhibitor (SGLT-2i) and metformin relative to monotherapy, utilizing the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database. Methods We extracted adverse event...